Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi

• Status: Terminated
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Albendazole and ivermectin are currently used in combination for annual mass treatment of lymphatic filariasis in Africa. Although the drugs have been donated, the cost of such programmes is very high and has proven to be a major impediment to the success of programmes in many countries with limited financial resources.

Data from albendazole treatment of other filarial infections and one study comparing single to multi-dose Diethycarbamazine/albendazole in lymphatic filariasis suggest that increased dose and/or frequency of albendazole dosing may be more effective in clearing microfilariae. It is essential to determine whether such higher doses are indeed beneficial since this could have far-reaching effects on the conduct and management of the main mass treatment programmes and also in the management of programmes as they near elimination.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: London School of Hygiene and Tropical Medicine
• Collaborator: Emory University
• Treatments: Albendazole; Ivermectin

Criteria

Inclusion Criteria:

• understand and sign informed consent

• willing to undergo night blood sampling every 6 months for 2 years

• Age 18 to 55 years

• Haemoglobin of equal or above 9g/dl

• Microfilarial level of equal or above 80mg/dl

Exclusion Criteria:

• Non- consenting

• Pregnancy or lactation

• Treatment with albendazole or ivermectin within the previous 6 months

• Known allergy to the study drugs